secwatch.observer — SEC 8-K summary
======================================

Issuer:     Imunon, Inc. (IMNN)
CIK:        0000749647
Form:       8-K
Filed at:   2023-12-11T23:59:59+00:00
Accession:  0001493152-23-044323
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Imunon appoints Dr. Sébastien Hazard as EVP and Chief Medical Officer
---------------------------------------------------------------------

- Dr. Hazard joins as EVP and CMO effective Dec. 11, 2023; previously Head of Clinical Development at Bicycle Therapeutics.
- Base salary of $475,000, target bonus of 50%; received inducement option for 80,000 shares at $0.88/share and 20,000 restricted shares.
- He will oversee clinical programs including IMNN-001 (IL-2) for ovarian cancer; topline data from OVATION 2 Study expected Q2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/749647/000149315223044323/0001493152-23-044323-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/749647/000149315223044323/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-044323

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer